C

ould we see an explosion of new anti-inflammatory therapies for heart disease?

Perhaps. That’s because Novartis may have just helped validate a long-standing theory: That targeting inflammation could play critical role in reducing the incidence of heart disease.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.